Ardelyx (ARDX) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 subdued as gains in banks offset AI jitters; Dow at one-month high
- Oil heads for weekly gain with focus on Middle East supply
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Vertiv shares fall on analyst downgrades and options bets
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Stocks edge lower as dollar heads for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
Ardelyx, Inc (ARDX) PT Raised to $13 at H.C. Wainwright
February 23, 2024 6:08 AM ESTH.C. Wainwright analyst Ed Arce raised the price target on Ardelyx, Inc (NASDAQ: ARDX) to $13.00 (from $11.00) while maintaining a Buy rating.
The analyst comments "We project U.S. IBSRELA annual net sales growth of 84% in 2024. Yesterday, Ardelyx announced 2023 U.S. IBSRELA net sales for irritable bowel syndrome (IBS-C) of $80.1M, largely in-line with... More



